

## **Medication Best Practices – Focus on Adherence**

Medication adherence can affect quality and length of life, health outcomes, and overall healthcare costs. A 2012 review in the Annals of Internal Medicine estimated that medication non-adherence costs the healthcare system between \$100 - \$289 billion a year. Adherence rates of 80% are needed for optimal therapeutic effect, however the estimated adherence rate in patients with chronic conditions hovers around 50 percent.

The Centers for Medicare & Medicaid Services consider medication adherence to be a critical component of health plan performance, and the measure is integral to an organization's Medicare Advantage Star Rating. Eight of the 45 unique measures in the Medicare Part C and D Star Ratings framework relate in some way to medications, and the three that relate directly to medication adherence in common chronic diseases are triple-weighted measures. Medication adherence is critical to improving health outcomes and lowering total cost of care.

Medication Adherence Measurements		
D10: Adherence for Diabetes Medications	D11: Adherence for Hypertension (RAS Antagonists)	D12: Adherence for Cholesterol (Statins)
Target Population		
<ul> <li>Are 18 years of age or older</li> <li>Have at least two fills in a calendar year for a diabetes (non-insulin) medication</li> <li>Biguanides</li> <li>DPP-IV inhibitors</li> <li>Incretin mimetics</li> <li>Meglitinides</li> <li>SGLT-2 inhibitors</li> <li>Sulfonylureas</li> <li>Thiazolidinediones</li> </ul>	<ul> <li>Are 18 years of age or older</li> <li>Have at least two fills in a calendar year for a reninangiotensin system antagonist</li> <li>ACE-inhibitors</li> <li>Angiotensin receptor blockers</li> <li>Direct renin inhibitors</li> </ul>	<ul> <li>Are 18 years of age or older</li> <li>Have at least two fills in a calendar year for a statin medication</li> </ul>
	Exclusions	
<ul> <li>Hospice enrollment</li> <li>ESRD diagnosis or coverage dates</li> <li>One or more prescriptions for insulin</li> </ul>	<ul> <li>Hospice enrollment</li> <li>ESRD diagnosis or coverage dates</li> <li>One or more prescriptions for sacubitril/valsartan</li> </ul>	<ul> <li>Hospice enrollment</li> <li>ESRD diagnosis or coverage dates</li> </ul>
Gap Closure		
<ul> <li>Patients fill their prescriptions of them</li> </ul>	ten enough to cover 80% or more of the	he time they are supposed to take

- Assess medication adherence at every patient interaction just as you do for vital signs
- Prioritize non-adherence in the differential for conditions not at goal
- Encourage patients to use tools like pill boxes, mobile apps, or multi-dose packaging as appropriate
- Review eligibility for 90-day prescriptions where permissible
- Provide a year's supply of prescriptions at each annual visit to prevent refill gaps
- Address concerns about medication safety, side effects, cost, or purpose
- Ask for patient input into their treatment plan
- Encourage annual comprehensive medication reviews with an aligned pharmacist



## References:

- Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 2012;157:785–95
- Neiman AB, Ruppar T, Ho M, et al. CDC Grand Rounds: Improving Medication Adherence for Chronic Disease Management — Innovations and Opportunities. MMWR Morb Mortal Wkly Rep 2017;66
- <a href="https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/Downloads/Star-Ratings-Technical-Notes-Oct-10-2019.pdf">https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/Downloads/Star-Ratings-Technical-Notes-Oct-10-2019.pdf</a>